Heart Rate News
-
Vivus Inc.’s shareholders are poised to reap an 88 percent windfall in a takeover after the company’s weight-loss drug moved one step closer to winning approval to treat America’s 78 million obese adults.
-
Vivus Inc. gained the most in 12 years after the company’s pill Qnexa won the backing of a regulatory panel, moving the drug a step closer to gaining U.S. approval as the first new obesity treatment in 13 years.
-
Chemicals used to enhance pictures obtained from medical imaging tests may lead to overactive or underactive thyroid glands, a study showed.
-
European and U.S. regulators are reviewing Novartis AG’s Gilenya pill for multiple sclerosis after reports of 11 deaths among patients who took the drug. The shares fell the most in more than five months.
-
Les Laboratoires Servier’s Procoralan, used to treat chest pain in Europe, reduced hospital stays and deaths from heart failure in high-risk patients, according to a study published in the journal The Lancet .
-
If you could spend a few minutes watching a gang of monkeys play, you’d soon identify the cautious “neophobes,” fearful of all things new, who peek at you from behind a barrier.
-
Argentina’s President Cristina Fernandez de Kirchner has been diagnosed with thyroid cancer, though tests show the tumor is contained and has shown no sign of spreading.
-
Step into the $285,000 Bentley Mulsanne and odd things happen. Your heart rate drops. The softball-sized knot between your shoulders shrinks to a marble.
-
The black Ford Explorer had a warning for the test driver at the lab in Dearborn, Michigan, last week: “It is important for you to recheck your blood glucose now.”
-
Vivus Inc. shares plunged the most ever in New York trading the day after U.S. reviewers recommended against approval of its Qnexa diet pill, a decision that analysts say may threaten makers of competing drugs.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page